Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03172156

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

Non-small Cell Lung Cancer Stage I Clinical Trial

Official title:
Multicentre, Prospective, Open Clinical Study of Postoperative ctDNA Dynamic Monitoring and Its Role of Prognosis in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)

Clinical Trial Summary

CtDNA detection is a noninvasive detection method, and the second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples. This project is to study the role of ctDNA dynamic monitoring of stage I NSCLC by NGS technique to verify the prognostic predictive effect of ctDNA .

Clinical Trial Description

CtDNA detection as a noninvasive detection method, can truly reflect the real tumor tissue gene mutation map and frequency, is the evaluation of therapeutic effect and the important monitoring indicators of clinical follow-up after treatment. The second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples. The ctDNA dynamic monitoring of stage I non-small cell lung cancer (NSCLC) was performed by the second generation gene sequencing (NGS) technique to verify the prognostic predictive effect of ctDNA in stage I NSCLC patients without radiotherapy and targeted therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03172156
Study type Observational
Source Sun Yat-sen University
Contact Si-Yu Wang, MD
Phone 86-20-87343439
Email wsysums@163.net
Status Recruiting
Phase N/A
Start date July 1, 2017
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Active, not recruiting NCT03603002 - Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer N/A
Completed NCT04342377 - The Canada Lymph Node Score Project: A Crossover Trial Phase 3
Recruiting NCT05097417 - Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer N/A
Recruiting NCT06341387 - Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Completed NCT01991418 - Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) N/A
Completed NCT03216551 - Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
Withdrawn NCT03431415 - Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Withdrawn NCT03029871 - Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer Phase 1
Active, not recruiting NCT06180239 - Segmentectomy vs Lobectomy
Active, not recruiting NCT03383302 - SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects Phase 1/Phase 2
Completed NCT04271384 - Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer Phase 2
Recruiting NCT02622581 - Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Not yet recruiting NCT02011997 - Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Phase 3
Recruiting NCT05453721 - Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529） N/A
Active, not recruiting NCT01795521 - LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC Phase 2
Recruiting NCT04944173 - SCION: SABR and Checkpoint Inhibition Of NSCLC Phase 2
Recruiting NCT04585477 - Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Phase 2